Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Neoplasms of the CNS

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 209 articles: HTML format

Single Articles

November 2023
1. SENRUNG A, Tripathi T, Yadav J, Janjua D, et al
   In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.
   BMC Cancer. 2023;23:1173.
   PubMed     Abstract available
   
   
   
2. ZHANG Y, Wu X, Zhu J, Lu R, et al
   Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression.
   BMC Cancer. 2023;23:1120.
   PubMed     Abstract available
   
   
   October 2023
3. SONG Y, Lin S, Chen J, Dang J, et al
   First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
   BMC Cancer. 2023;23:1043.
   PubMed     Abstract available
   
   
   
4. WEI D, Niu B, Zhai B, Liu XB, et al
   Expression profiles and function prediction of tRNA-derived fragments in glioma.
   BMC Cancer. 2023;23:1015.
   PubMed     Abstract available
   
   
   
5. YANG XS, Zhu P, Xie RX, Chen PF, et al
   Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image.
   BMC Cancer. 2023;23:1012.
   PubMed     Abstract available
   
   
   
6. ROZATI H, Chen J, Williams M
   Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis.
   BMC Cancer. 2023;23:1004.
   PubMed     Abstract available
   
   
   
7. WANG Z, Cui Y, Wang F, Xu L, et al
   DNA methylation-regulated LINC02587 inhibits ferroptosis and promotes the progression of glioma cells through the CoQ-FSP1 pathway.
   BMC Cancer. 2023;23:989.
   PubMed     Abstract available
   
   
   
8. VINCENT CA, Nissen I, Dakhel S, Hornblad A, et al
   Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
   BMC Cancer. 2023;23:945.
   PubMed     Abstract available
   
   
   
9. ROBINSON SD, Samuels M, Jones W, Gilbert D, et al
   Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
   BMC Cancer. 2023;23:939.
   PubMed     Abstract available
   
   
   
10. MING Y, Luo C, Ji B, Cheng J, et al
    ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    BMC Cancer. 2023;23:937.
    PubMed     Abstract available
    
    
    September 2023
11. CHENG WY, Shen CC, Liang YJ, Chiao MT, et al
    Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
    BMC Cancer. 2023;23:886.
    PubMed     Abstract available
    
    
    
12. HATTORI EY, Arakawa Y, Mineharu Y, Furukawa K, et al
    Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
    BMC Cancer. 2023;23:849.
    PubMed     Abstract available
    
    
    
13. SHAN E, Cao YN, Zhang Y, Chen W, et al
    Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:846.
    PubMed     Abstract available
    
    
    
14. LIU Z, Hong X, Wang L, Ma Z, et al
    Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas.
    BMC Cancer. 2023;23:848.
    PubMed     Abstract available
    
    
    August 2023
15. MIRANDA J, Vazquez-Blomquist D, Bringas R, Fernandez-de-Cossio J, et al
    A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
    BMC Cancer. 2023;23:806.
    PubMed     Abstract available
    
    
    
16. TAN C, Wei J, Li Z, Tian N, et al
    Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma.
    BMC Cancer. 2023;23:808.
    PubMed     Abstract available
    
    
    
17. WANG X, Chen J, Lei Z, Chen H, et al
    Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus‑avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple i
    BMC Cancer. 2023;23:796.
    PubMed     Abstract available
    
    
    
18. NEUTEL CLG, Viozzi I, Overduin CG, Rijpma A, et al
    Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
    BMC Cancer. 2023;23:788.
    PubMed     Abstract available
    
    
    
19. SOUSA N, Geiss C, Bindila L, Lieberwirth I, et al
    Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
    BMC Cancer. 2023;23:762.
    PubMed     Abstract available
    
    
    
20. ZHAO N, Weng S, Liu Z, Xu H, et al
    CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    BMC Cancer. 2023;23:749.
    PubMed     Abstract available
    
    
    
21. ZHONG K, Shi Y, Gao Y, Zhang H, et al
    First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    BMC Cancer. 2023;23:746.
    PubMed     Abstract available
    
    
    
22. LI J, Guo Q, Xing R
    Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    BMC Cancer. 2023;23:727.
    PubMed     Abstract available
    
    
    July 2023
23. TAN Q, Wang Q, Jin S, Zhou F, et al
    Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers.
    BMC Cancer. 2023;23:712.
    PubMed     Abstract available
    
    
    
24. CHIEN CH, Lai CC, Chuang JY, Chu JM, et al
    Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
    BMC Cancer. 2023;23:713.
    PubMed     Abstract available
    
    
    
25. WALTENBERGER M, Bernhardt D, Diehl C, Gempt J, et al
    Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
    BMC Cancer. 2023;23:709.
    PubMed     Abstract available
    
    
    
26. TAO R, Huang R, Yang J, Wang J, et al
    Comprehensive analysis of the clinical and biological significances of cholesterol metabolism in lower-grade gliomas.
    BMC Cancer. 2023;23:692.
    PubMed     Abstract available
    
    
    
27. YUEYANG M, Yaqin H, Guolian X, Wenjian Z, et al
    Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text]/VEGF-A signaling axis.
    BMC Cancer. 2023;23:662.
    PubMed     Abstract available
    
    
    June 2023
28. PENG Y, Liu H, Wu Q, Wang L, et al
    Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    BMC Cancer. 2023;23:596.
    PubMed     Abstract available
    
    
    
29. XUE Z, Wang J, Wang Z, Liu J, et al
    SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
    BMC Cancer. 2023;23:589.
    PubMed     Abstract available
    
    
    
30. SUN S, Yang C, Wang K, Huang R, et al
    Molecular and clinical characterization of PTRF in glioma via 1,022 samples.
    BMC Cancer. 2023;23:551.
    PubMed     Abstract available
    
    
    
31. WEI L, Pan M, Jiang Q, Hu B, et al
    Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway.
    BMC Cancer. 2023;23:550.
    PubMed     Abstract available
    
    
    
32. FU M, Zhou Z, Huang X, Chen Z, et al
    Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
    BMC Cancer. 2023;23:544.
    PubMed     Abstract available
    
    
    
33. HAO Z, Huajun S, Zhen G, Yu X, et al
    AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
    BMC Cancer. 2023;23:516.
    PubMed     Abstract available
    
    
    
34. BABAZADEH SM, Zolfaghari MR, Zargar M, Baesi K, et al
    Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.
    BMC Cancer. 2023;23:519.
    PubMed     Abstract available
    
    
    May 2023
35. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
    Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
    BMC Cancer. 2023;23:468.
    PubMed     Abstract available
    
    
    
36. CHEN Y, Ma F, Zhang Z, Guo Y, et al
    LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
    BMC Cancer. 2023;23:455.
    PubMed     Abstract available
    
    
    
37. DUAN X, Yang B, Zhao C, Tie B, et al
    Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
    BMC Cancer. 2023;23:432.
    PubMed     Abstract available
    
    
    
38. LIU ZY, Lan T, Tang F, He YZ, et al
    ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:420.
    PubMed     Abstract available
    
    
    
39. WANG X, Zhang H, Zhang M, Zhang X, et al
    Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
    BMC Cancer. 2023;23:415.
    PubMed     Abstract available
    
    
    
40. ZOU R, Zhong X, Liang K, Zhi C, et al
    Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    BMC Cancer. 2023;23:403.
    PubMed     Abstract available
    
    
    April 2023
41. THIVAT E, Casile M, Moreau J, Molnar I, et al
    Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
    BMC Cancer. 2023;23:344.
    PubMed     Abstract available
    
    
    
42. ZHOU T, Zhu S, Xiong Q, Gan J, et al
    Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2023;23:333.
    PubMed     Abstract available
    
    
    
43. KELLER KM, Koetsier J, Schild L, Amo-Addae V, et al
    The potential of PARP as a therapeutic target across pediatric solid malignancies.
    BMC Cancer. 2023;23:310.
    PubMed     Abstract available
    
    
    March 2023
44. WANG H, Xing R, Li M, Zhang M, et al
    Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
    BMC Cancer. 2023;23:289.
    PubMed     Abstract available
    
    
    
45. CROUZEN JA, Petoukhova AL, Broekman MLD, Fiocco M, et al
    SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
    BMC Cancer. 2023;23:273.
    PubMed     Abstract available
    
    
    
46. KING AL, Acquaye-Mallory AA, Vera E, Mendoza T, et al
    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
    BMC Cancer. 2023;23:262.
    PubMed     Abstract available
    
    
    
47. LIU X, Li Z, Sun J, Zhang Z, et al
    Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
    BMC Cancer. 2023;23:259.
    PubMed     Abstract available
    
    
    
48. ZHANG M, Liu X, Wang D, Ruan X, et al
    A novel cuproptosis-related gene signature to predict prognosis in Glioma.
    BMC Cancer. 2023;23:237.
    PubMed     Abstract available
    
    
    
49. CAIN SA, Pope B, Mangiola S, Mantamadiotis T, et al
    Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
    BMC Cancer. 2023;23:216.
    PubMed     Abstract available
    
    
    
50. XU Z, Hao X, Wang Q, Yang K, et al
    Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
    BMC Cancer. 2023;23:206.
    PubMed     Abstract available
    
    
    
51. GEURTS BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, et al
    Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    BMC Cancer. 2023;23:205.
    PubMed     Abstract available
    
    
    February 2023
52. MADDISON K, Bowden NA, Graves MC, Tooney PA, et al
    Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review.
    BMC Cancer. 2023;23:185.
    PubMed     Abstract available
    
    
    
53. QUESNEL A, Coles N, Angione C, Dey P, et al
    Glycosylation spectral signatures for glioma grade discrimination using Raman spectroscopy.
    BMC Cancer. 2023;23:174.
    PubMed     Abstract available
    
    
    
54. ZHU H, Tan J, Pan X, Ouyang H, et al
    HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas.
    BMC Cancer. 2023;23:125.
    PubMed     Abstract available
    
    
    
55. ZHU X, Chen D, Sun Y, Yang S, et al
    LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
    BMC Cancer. 2023;23:120.
    PubMed     Abstract available
    
    
    January 2023
56. DAI L, Guo X, Xing Z, Tao Y, et al
    Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
    BMC Cancer. 2023;23:102.
    PubMed     Abstract available
    
    
    
57. ZHANG GT, Liu Q, Zuo FX, Liu HJ, et al
    Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
    BMC Cancer. 2023;23:104.
    PubMed     Abstract available
    
    
    
58. LILJEDAHL E, Konradsson E, Gustafsson E, Jonsson KF, et al
    Combined anti-C1-INH and radiotherapy against glioblastoma.
    BMC Cancer. 2023;23:106.
    PubMed     Abstract available
    
    
    
59. LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
    Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    BMC Cancer. 2023;23:78.
    PubMed     Abstract available
    
    
    
60. LI L, Zhang C, Wang Z, Wang Y, et al
    Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data.
    BMC Cancer. 2023;23:42.
    PubMed     Abstract available
    
    
    
61. WANG X, Li X, Wu Y, Hong J, et al
    The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification).
    BMC Cancer. 2023;23:20.
    PubMed     Abstract available
    
    
    
62. LI C, Xi S, Chen Y, Guo C, et al
    Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center.
    BMC Cancer. 2023;23:8.
    PubMed     Abstract available
    
    
    December 2022
63. DAS S, Faruqi S, Nordal R, Starreveld Y, et al
    A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases.
    BMC Cancer. 2022;22:1368.
    PubMed     Abstract available
    
    
    
64. ZHU Y, Teng Y, Xu S, Xu Y, et al
    Eczema as a protective factor for brain cancer: a meta-analysis.
    BMC Cancer. 2022;22:1360.
    PubMed     Abstract available
    
    
    
65. PENG D, Liang P, Zhong C, Xu P, et al
    Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
    BMC Cancer. 2022;22:1323.
    PubMed     Abstract available
    
    
    
66. ZWAIG M, Baguette A, Hu B, Johnston M, et al
    Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data.
    BMC Cancer. 2022;22:1297.
    PubMed     Abstract available
    
    
    
67. SHANG K, Huang H, Xu Y, Liu Y, et al
    Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
    BMC Cancer. 2022;22:1295.
    PubMed     Abstract available
    
    
    
68. ZHAO S, Ji W, Shen Y, Fan Y, et al
    Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
    BMC Cancer. 2022;22:1274.
    PubMed     Abstract available
    
    
    
69. TOMITA N, Ishiyama H, Makita C, Ohshima Y, et al
    Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial.
    BMC Cancer. 2022;22:1259.
    PubMed     Abstract available
    
    
    November 2022
70. KIM JW, Park SH, Choi SA, Kim SK, et al
    Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
    BMC Cancer. 2022;22:1221.
    PubMed     Abstract available
    
    
    
71. LIU X, Yang J, Li H, Wang Q, et al
    Quantifying substantial carcinogenesis of genetic and environmental factors from measurement error in the number of stem cell divisions.
    BMC Cancer. 2022;22:1194.
    PubMed     Abstract available
    
    
    
72. ZHANG Y, Wang X, Shi M, Song Y, et al
    Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma.
    BMC Cancer. 2022;22:1171.
    PubMed     Abstract available
    
    
    October 2022
73. GALLITTO M, Savacool M, Lee A, Wang TJC, et al
    Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
    BMC Cancer. 2022;22:1095.
    PubMed     Abstract available
    
    
    September 2022
74. CHEN Z, Zhou L, Zhao M, Cao K, et al
    Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
    BMC Cancer. 2022;22:1010.
    PubMed     Abstract available
    
    
    
75. CHOI JM, Lim SH, Liu ZP, Lee TK, et al
    Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model.
    BMC Cancer. 2022;22:986.
    PubMed     Abstract available
    
    
    
76. TU Z, Ji Q, Han Q, Long X, et al
    Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
    BMC Cancer. 2022;22:973.
    PubMed     Abstract available
    
    
    
77. WENDLER J, Fox CP, Valk E, Steinheber C, et al
    Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
    BMC Cancer. 2022;22:971.
    PubMed     Abstract available
    
    
    August 2022
78. HUANG Y, Ouyang F, Yang F, Zhang N, et al
    The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.
    BMC Cancer. 2022;22:900.
    PubMed     Abstract available
    
    
    
79. YU H, Gong M, Qi J, Zhao C, et al
    Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
    BMC Cancer. 2022;22:885.
    PubMed     Abstract available
    
    
    
80. JIANG L, Yang J, Xu Q, Lv K, et al
    Machine learning for the micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in glioblastoma.
    BMC Cancer. 2022;22:882.
    PubMed     Abstract available
    
    
    
81. SCHULZ JA, Rodgers LT, Kryscio RJ, Hartz AMS, et al
    Characterization and comparison of human glioblastoma models.
    BMC Cancer. 2022;22:844.
    PubMed     Abstract available
    
    
    
82. ROY C, Avril S, Legendre C, Lelievre B, et al
    A role for ceruloplasmin in the control of human glioblastoma cell responses to radiation.
    BMC Cancer. 2022;22:843.
    PubMed     Abstract available
    
    
    July 2022
83. GUAN Y, Pan M, Yang J, Lu Q, et al
    A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
    BMC Cancer. 2022;22:827.
    PubMed     Abstract available
    
    
    
84. YU J, Gao G, Wei X, Wang Y, et al
    TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
    BMC Cancer. 2022;22:786.
    PubMed     Abstract available
    
    
    
85. ABUHAMED J, Nikkila A, Raitanen J, Alimam W, et al
    Incidence trends of childhood central nervous system tumors in Finland 1990-2017.
    BMC Cancer. 2022;22:784.
    PubMed     Abstract available
    
    
    
86. WU X, Li C, Wang Z, Zhang Y, et al
    A bioinformatic analysis study of m(7)G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma.
    BMC Cancer. 2022;22:729.
    PubMed     Abstract available
    
    
    June 2022
87. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
    Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
    BMC Cancer. 2022;22:713.
    PubMed     Abstract available
    
    
    
88. WANG J, Qiu X, Huang J, Zhuo Z, et al
    Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme.
    BMC Cancer. 2022;22:644.
    PubMed     Abstract available
    
    
    
89. WICK A, Sander A, Koch M, Bendszus M, et al
    Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    BMC Cancer. 2022;22:645.
    PubMed     Abstract available
    
    
    
90. MALA U, Baral TK, Somasundaram K
    Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    BMC Cancer. 2022;22:642.
    PubMed     Abstract available
    
    
    
91. DING MR, Qu YJ, Peng X, Chen JF, et al
    Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
    BMC Cancer. 2022;22:611.
    PubMed     Abstract available
    
    
    
92. GATELY L, Drummond K, Rosenthal M, Harrup R, et al
    Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry).
    BMC Cancer. 2022;22:604.
    PubMed     Abstract available
    
    
    May 2022
93. YANG H, Wen L, Pan Y, Shan C, et al
    Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    BMC Cancer. 2022;22:580.
    PubMed     Abstract available
    
    
    
94. XU X, Yuan H, Pan J, Chen W, et al
    The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.
    BMC Cancer. 2022;22:499.
    PubMed     Abstract available
    
    
    
95. FISCHER GF, Brugge D, Andratschke N, Baumert BG, et al
    Postoperative radiotherapy for meningiomas - a decision-making analysis.
    BMC Cancer. 2022;22:492.
    PubMed     Abstract available
    
    
    April 2022
96. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
    Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
    BMC Cancer. 2022;22:473.
    PubMed     Abstract available
    
    
    
97. LI J, Wang J, Ding Y, Zhao J, et al
    Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    BMC Cancer. 2022;22:466.
    PubMed     Abstract available
    
    
    
98. ZHANG J, Guo Z, Xie Q, Zhong C, et al
    Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-kappaB signaling pathway.
    BMC Cancer. 2022;22:457.
    PubMed     Abstract available
    
    
    
99. KLEINBERGER I, Sanders E, Staes K, Van Troys M, et al
    Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.
    BMC Cancer. 2022;22:451.
    PubMed     Abstract available
    
    
    
100. ARUNACHALAM E, Rogers W, Simpson GR, Moller-Levet C, et al
     HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme.
     BMC Cancer. 2022;22:400.
     PubMed     Abstract available
     
     
     
101. WANG C, Liu C, Chen J, Jiang H, et al
     Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.
     BMC Cancer. 2022;22:397.
     PubMed     Abstract available
     
     
     
102. BELANGER K, Ung TH, Damek D, Lillehei KO, et al
     Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
     BMC Cancer. 2022;22:367.
     PubMed     Abstract available
     
     
     March 2022
103. RYDEN I, Thurin E, Carstam L, Smits A, et al
     Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
     BMC Cancer. 2022;22:350.
     PubMed    
     
     
     
104. SANDER C, Frydrychowicz C, Prasse G, Taubenheim S, et al
     The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series.
     BMC Cancer. 2022;22:336.
     PubMed     Abstract available
     
     
     
105. HESSLER N, Junger ST, Meissner AK, Kocher M, et al
     Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
     BMC Cancer. 2022;22:275.
     PubMed     Abstract available
     
     
     
106. EGGEN AC, Hospers GAP, Bosma I, Kramer MCA, et al
     Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
     BMC Cancer. 2022;22:247.
     PubMed     Abstract available
     
     
     
107. BI Y, Wu ZH, Cao F
     Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
     BMC Cancer. 2022;22:233.
     PubMed     Abstract available
     
     
     
108. PUHAKKA I, Kuitunen H, Jakala P, Sonkajarvi E, et al
     Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.
     BMC Cancer. 2022;22:236.
     PubMed     Abstract available
     
     
     
109. LI C, Liu F, Sun L, Liu Z, et al
     Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
     BMC Cancer. 2022;22:230.
     PubMed     Abstract available
     
     
     February 2022
110. MOU Y, Zhang L, Liu Z, Song X, et al
     Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
     BMC Cancer. 2022;22:215.
     PubMed     Abstract available
     
     
     
111. WANG X, Wang Y, Xie F, Song ZT, et al
     Norepinephrine promotes glioma cell migration through up-regulating the expression of Twist1.
     BMC Cancer. 2022;22:213.
     PubMed     Abstract available
     
     
     
112. FU J, Zeng J, Huang M, Liang S, et al
     Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study.
     BMC Cancer. 2022;22:206.
     PubMed     Abstract available
     
     
     
113. ZENG Y, Guo T, Zhou Y, Zhao Y, et al
     Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
     BMC Cancer. 2022;22:198.
     PubMed     Abstract available
     
     
     
114. ZHANG X, Wu Y, Sun X, Cui Q, et al
     The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
     BMC Cancer. 2022;22:190.
     PubMed     Abstract available
     
     
     
115. BUENO-MARTINEZ E, Lara-Almunia M, Rodriguez-Arias C, Otero-Rodriguez A, et al
     Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.
     BMC Cancer. 2022;22:146.
     PubMed     Abstract available
     
     
     
116. TRIPATHI PH, Akhtar J, Arora J, Saran RK, et al
     Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
     BMC Cancer. 2022;22:133.
     PubMed     Abstract available
     
     
     January 2022
117. WEI R, Zhao C, Li J, Yang F, et al
     Online calculator to predict early mortality in patient with surgically treated recurrent lower-grade glioma.
     BMC Cancer. 2022;22:114.
     PubMed     Abstract available
     
     
     
118. MAO XG, Xue XY, Wang L, Lin W, et al
     Deep learning identified glioblastoma subtypes based on internal genomic expression ranks.
     BMC Cancer. 2022;22:86.
     PubMed     Abstract available
     
     
     
119. REN J, Zhang X, Cao J, Tian J, et al
     Radiosynthesis of a novel antisense imaging probe targeting LncRNA HOTAIR in malignant glioma.
     BMC Cancer. 2022;22:79.
     PubMed     Abstract available
     
     
     
120. SCHAFF LR, Lobbous M, Carlow D, Schofield R, et al
     Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
     BMC Cancer. 2022;22:60.
     PubMed     Abstract available
     
     
     
121. HOSEINI B, Rahmatinejad Z, Goshayeshi L, Bergquist R, et al
     Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry.
     BMC Cancer. 2022;22:48.
     PubMed     Abstract available
     
     
     
122. ALVAREZ-TORRES MDM, Fuster-Garcia E, Juan-Albarracin J, Reynes G, et al
     Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
     BMC Cancer. 2022;22:40.
     PubMed     Abstract available
     
     
     December 2021
123. RAYMOND P, Klein M, Cuny T, Klein O, et al
     High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas.
     BMC Cancer. 2021;21:1346.
     PubMed     Abstract available
     
     
     
124. ZHANG M, Cheng Y, Xue Z, Sun Q, et al
     A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
     BMC Cancer. 2021;21:1311.
     PubMed     Abstract available
     
     
     November 2021
125. MACHARIA LW, Muriithi W, Heming CP, Nyaga DK, et al
     The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.
     BMC Cancer. 2021;21:1248.
     PubMed     Abstract available
     
     
     
126. POON MTC, Bruce M, Simpson JE, Hannan CJ, et al
     Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
     BMC Cancer. 2021;21:1240.
     PubMed     Abstract available
     
     
     
127. WEN J, Rusch M, Brady SW, Shao Y, et al
     The landscape of coding RNA editing events in pediatric cancer.
     BMC Cancer. 2021;21:1233.
     PubMed     Abstract available
     
     
     
128. XIE H, Yuan C, Ding XH, Li JJ, et al
     Identification of key genes and pathways associated with resting mast cells in meningioma.
     BMC Cancer. 2021;21:1209.
     PubMed     Abstract available
     
     
     
129. DJUZENOVA CS, Fischer T, Katzer A, Sisario D, et al
     Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
     BMC Cancer. 2021;21:1201.
     PubMed     Abstract available
     
     
     
130. SU X, Yang Y, Yang Q, Pang B, et al
     NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma.
     BMC Cancer. 2021;21:1181.
     PubMed     Abstract available
     
     
     
131. XIE Y, Gong C, Zhang J, Wang L, et al
     Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
     BMC Cancer. 2021;21:1174.
     PubMed     Abstract available
     
     
     October 2021
132. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
     Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
     BMC Cancer. 2021;21:1168.
     PubMed     Abstract available
     
     
     
133. ARAKAWA Y, Sasaki K, Mineharu Y, Uto M, et al
     A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
     BMC Cancer. 2021;21:1105.
     PubMed     Abstract available
     
     
     
134. KEMMERER CL, Schittenhelm J, Dubois E, Neumann L, et al
     Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.
     BMC Cancer. 2021;21:1108.
     PubMed     Abstract available
     
     
     
135. LIU R, Dai W, Wu A, Li Y, et al
     CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis.
     BMC Cancer. 2021;21:1090.
     PubMed     Abstract available
     
     
     September 2021
136. CHENG S, Yang L, Dai X, Wang J, et al
     The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
     BMC Cancer. 2021;21:1057.
     PubMed     Abstract available
     
     
     
137. MAKINO Y, Arakawa Y, Yoshioka E, Shofuda T, et al
     Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
     BMC Cancer. 2021;21:1025.
     PubMed     Abstract available
     
     
     
138. TYLDESLEY-MARSHALL N, Greenfield S, Neilson SJ, English M, et al
     The role of Magnetic Resonance Images (MRIs) in coping for patients with brain tumours and their parents: a qualitative study.
     BMC Cancer. 2021;21:1013.
     PubMed     Abstract available
     
     
     
139. MIKIC N, Poulsen FR, Kristoffersen KB, Laursen RJ, et al
     Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
     BMC Cancer. 2021;21:1010.
     PubMed     Abstract available
     
     
     August 2021
140. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
     Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
     BMC Cancer. 2021;21:967.
     PubMed     Abstract available
     
     
     
141. LI Y, Guo D
     Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
     BMC Cancer. 2021;21:958.
     PubMed     Abstract available
     
     
     
142. KIM YJ, Oh H, Lee SJ, Kim KM, et al
     Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
     BMC Cancer. 2021;21:942.
     PubMed     Abstract available
     
     
     
143. XIAO J, Xu L, Ding Y, Wang W, et al
     Does post-operative radiotherapy improve the treatment outcomes of intracranial hemangiopericytoma? A retrospective study.
     BMC Cancer. 2021;21:915.
     PubMed     Abstract available
     
     
     July 2021
144. WANG X, Cai J, Zeng Z, Liu A, et al
     Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
     BMC Cancer. 2021;21:873.
     PubMed     Abstract available
     
     
     
145. GINZAC A, Dupic G, Brun L, Molnar I, et al
     Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.
     BMC Cancer. 2021;21:864.
     PubMed     Abstract available
     
     
     
146. ASANO K, Fumoto T, Matsuzaka M, Hasegawa S, et al
     Combination chemoradiotherapy with temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
     BMC Cancer. 2021;21:867.
     PubMed     Abstract available
     
     
     
147. SYAFRUDDIN SE, Nazarie WFWM, Moidu NA, Soon BH, et al
     Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
     BMC Cancer. 2021;21:850.
     PubMed     Abstract available
     
     
     
148. HUANG T, Chen Y, Zeng Y, Xu C, et al
     Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
     BMC Cancer. 2021;21:844.
     PubMed     Abstract available
     
     
     
149. ZHANG F, He Q, Luo G, Long Y, et al
     The combination of (13)N-ammonia and (11)C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.
     BMC Cancer. 2021;21:837.
     PubMed     Abstract available
     
     
     
150. SHEN H, Deng G, Chen Q, Qian J, et al
     The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
     BMC Cancer. 2021;21:825.
     PubMed     Abstract available
     
     
     June 2021
151. SCHEICHEL F, Marhold F, Pinggera D, Kiesel B, et al
     Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.
     BMC Cancer. 2021;21:754.
     PubMed     Abstract available
     
     
     
152. LU J, Peng Y, Huang R, Feng Z, et al
     Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
     BMC Cancer. 2021;21:723.
     PubMed     Abstract available
     
     
     
153. TU Z, Xiong H, Qiu Y, Li G, et al
     Limited recurrence distance of glioblastoma under modern radiotherapy era.
     BMC Cancer. 2021;21:720.
     PubMed     Abstract available
     
     
     
154. ZHU W, Zhao H, Xu F, Huang B, et al
     The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
     BMC Cancer. 2021;21:664.
     PubMed     Abstract available
     
     
     
155. MOON HH, Kim HS, Park JE, Kim YH, et al
     Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
     BMC Cancer. 2021;21:654.
     PubMed     Abstract available
     
     
     May 2021
156. SHAN Q, Shi J, Wang X, Guo J, et al
     A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
     BMC Cancer. 2021;21:640.
     PubMed     Abstract available
     
     
     
157. ZHU J, Wang H, Sun Q, Ji X, et al
     Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells.
     BMC Cancer. 2021;21:582.
     PubMed    
     
     
     
158. MILLS MN, Naz A, Thawani C, Walker C, et al
     Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
     BMC Cancer. 2021;21:552.
     PubMed     Abstract available
     
     
     
159. MAJCHRZAK-CELINSKA A, Misiorek JO, Kruhlenia N, Przybyl L, et al
     COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/beta-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
     BMC Cancer. 2021;21:493.
     PubMed     Abstract available
     
     
     April 2021
160. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
     New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
     BMC Cancer. 2021;21:476.
     PubMed     Abstract available
     
     
     
161. XU B, Huo Z, Huang H, Ji W, et al
     The expression and prognostic value of the epidermal growth factor receptor family in glioma.
     BMC Cancer. 2021;21:451.
     PubMed     Abstract available
     
     
     
162. AMIN S, Baine M, Meza J, Lin C, et al
     The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
     BMC Cancer. 2021;21:387.
     PubMed     Abstract available
     
     
     
163. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
     A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
     BMC Cancer. 2021;21:386.
     PubMed     Abstract available
     
     
     March 2021
164. KUO CS, Tung PH, Huang AC, Wang CC, et al
     A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
     BMC Cancer. 2021;21:309.
     PubMed     Abstract available
     
     
     
165. XI J, Hassan B, Katumba RGN, Khaddour K, et al
     The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
     BMC Cancer. 2021;21:285.
     PubMed     Abstract available
     
     
     
166. KIANG KM, Chan AA, Leung GK
     Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
     BMC Cancer. 2021;21:265.
     PubMed     Abstract available
     
     
     
167. ZHANG C, Liu H, Xu P, Tan Y, et al
     Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
     BMC Cancer. 2021;21:251.
     PubMed     Abstract available
     
     
     
168. RYDEN I, Thurin E, Carstam L, Smits A, et al
     Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
     BMC Cancer. 2021;21:248.
     PubMed     Abstract available
     
     
     
169. MILLS MN, Walker C, Thawani C, Naz A, et al
     Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
     BMC Cancer. 2021;21:223.
     PubMed     Abstract available
     
     
     
170. MASALHA W, Daka K, Woerner J, Pompe N, et al
     Metabolic alterations in meningioma reflect the clinical course.
     BMC Cancer. 2021;21:211.
     PubMed     Abstract available
     
     
     February 2021
171. ZHANG Y, Zou D, Yin J, Zhang L, et al
     Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
     BMC Cancer. 2021;21:183.
     PubMed     Abstract available
     
     
     
172. KHAN M, Zhao Z, Arooj S, Liao G, et al
     Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
     BMC Cancer. 2021;21:167.
     PubMed     Abstract available
     
     
     
173. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
     One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
     BMC Cancer. 2021;21:140.
     PubMed     Abstract available
     
     
     
174. GUAN Y, Xiong J, Pan M, Shi W, et al
     Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
     BMC Cancer. 2021;21:123.
     PubMed     Abstract available
     
     
     January 2021
175. LIU G, Liu D, Huang J, Li J, et al
     Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
     BMC Cancer. 2021;21:98.
     PubMed     Abstract available
     
     
     
176. LIU FM, Gao YF, Kong Y, Guan Y, et al
     The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
     BMC Cancer. 2021;21:83.
     PubMed     Abstract available
     
     
     
177. WEN J, Chen W, Zhu Y, Zhang P, et al
     Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
     BMC Cancer. 2021;21:81.
     PubMed     Abstract available
     
     
     
178. CHEN B, Chen C, Zhang Y, Xu J, et al
     Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
     BMC Cancer. 2021;21:54.
     PubMed     Abstract available
     
     
     
179. WANG Y, Zhang Y, Hong Y, Zeng P, et al
     Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
     BMC Cancer. 2021;21:25.
     PubMed     Abstract available
     
     
     December 2020
180. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
     Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
     BMC Cancer. 2020;20:1213.
     PubMed     Abstract available
     
     
     
181. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
     Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
     BMC Cancer. 2020;20:1210.
     PubMed     Abstract available
     
     
     November 2020
182. YU X, Wang Y, Yuan Z, Yu H, et al
     Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
     BMC Cancer. 2020;20:1144.
     PubMed     Abstract available
     
     
     
183. LI X, Meng Y
     Analyses of metastasis-associated genes in IDH wild-type glioma.
     BMC Cancer. 2020;20:1114.
     PubMed     Abstract available
     
     
     
184. ZHU Z, Lan Y, Wang L, Ge J, et al
     A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
     BMC Cancer. 2020;20:1072.
     PubMed     Abstract available
     
     
     
185. AFTAHY AK, Barz M, Krauss P, Liesche F, et al
     Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
     BMC Cancer. 2020;20:1060.
     PubMed     Abstract available
     
     
     October 2020
186. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
     Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
     BMC Cancer. 2020;20:1045.
     PubMed     Abstract available
     
     
     
187. DING X, Yang L, Geng X, Zou Y, et al
     CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
     BMC Cancer. 2020;20:1005.
     PubMed     Abstract available
     
     
     
188. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
     Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
     BMC Cancer. 2020;20:991.
     PubMed     Abstract available
     
     
     
189. FENG J, Ouyang Y, Xu D, He Q, et al
     Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
     BMC Cancer. 2020;20:976.
     PubMed     Abstract available
     
     
     
190. HONG KT, Lee DH, Kim BK, An HY, et al
     Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients.
     BMC Cancer. 2020;20:979.
     PubMed     Abstract available
     
     
     
191. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
     Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
     BMC Cancer. 2020;20:973.
     PubMed     Abstract available
     
     
     September 2020
192. WANG J, Tong L, Lin G, Wang H, et al
     Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
     BMC Cancer. 2020;20:931.
     PubMed     Abstract available
     
     
     
193. DU F, Hou Q
     SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.
     BMC Cancer. 2020;20:839.
     PubMed     Abstract available
     
     
     August 2020
194. COSTE A, Bailey HD, Kartal-Kaess M, Renella R, et al
     Parental occupational exposure to pesticides and risk of childhood cancer in Switzerland: a census-based cohort study.
     BMC Cancer. 2020;20:819.
     PubMed     Abstract available
     
     
     
195. HEILAND DH, Ohle R, Cipriani D, Franco P, et al
     Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
     BMC Cancer. 2020;20:818.
     PubMed     Abstract available
     
     
     July 2020
196. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
     Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
     BMC Cancer. 2020;20:702.
     PubMed     Abstract available
     
     
     
197. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
     Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
     BMC Cancer. 2020;20:690.
     PubMed     Abstract available
     
     
     
198. LIN J, Yu L, Fu Y, Chen H, et al
     A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
     BMC Cancer. 2020;20:630.
     PubMed     Abstract available
     
     
     
199. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
     Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
     BMC Cancer. 2020;20:615.
     PubMed     Abstract available
     
     
     June 2020
200. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
     Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
     BMC Cancer. 2020;20:610.
     PubMed     Abstract available
     
     
     
201. XU T, Zhang X, Zhang S, Liu C, et al
     Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
     BMC Cancer. 2020;20:596.
     PubMed     Abstract available
     
     
     
202. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
     Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
     BMC Cancer. 2020;20:532.
     PubMed     Abstract available
     
     
     
203. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
     Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
     BMC Cancer. 2020;20:501.
     PubMed     Abstract available
     
     
     May 2020
204. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
     Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
     BMC Cancer. 2020;20:460.
     PubMed     Abstract available
     
     
     
205. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
     A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
     BMC Cancer. 2020;20:370.
     PubMed     Abstract available
     
     
     April 2020
206. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
     PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
     BMC Cancer. 2020;20:277.
     PubMed     Abstract available
     
     
     March 2020
207. NAWROCKI S, Sugajska A
     Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
     BMC Cancer. 2020;20:231.
     PubMed     Abstract available
     
     
     February 2020
208. CHO I, Lee H, Yoon SE, Ryu KJ, et al
     Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
     BMC Cancer. 2020;20:120.
     PubMed     Abstract available
     
     
     
209. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
     The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
     BMC Cancer. 2020;20:88.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.